Anne Phelan
Hoofd Techniek/Wetenschap/O&O bij BENEVOLENTAI
Actieve functies van Anne Phelan
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BENEVOLENTAI | Hoofd Techniek/Wetenschap/O&O | 01-11-2019 | - |
BenevolentAI Cambridge Ltd.
 BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Directeur/Bestuurslid | 03-01-2019 | - |
BenevolentAI Ltd.
 BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Hoofd Techniek/Wetenschap/O&O | 01-09-2019 | - |
Loopbaan van Anne Phelan
Eerdere bekende functies van Anne Phelan
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | 01-01-2018 | 01-11-2018 |
| PFIZER, INC. | Corporate Officer/Principal | 01-04-2014 | 01-10-2015 |
Opleiding van Anne Phelan
| University of Liverpool | Doctorate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 6 |
| Verenigde Staten | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Commercial Services | 2 |
| Technology Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BENEVOLENTAI | Health Technology |
| PFIZER, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
BenevolentAI Cambridge Ltd.
BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Commercial Services |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Technology Services |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Anne Phelan
- Ervaring
